Related Experiment Video

Updated: Feb 8, 2026

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma
07:01

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

21.7K

Interactions of Vascular Endothelial Growth Factor and p53 with miR-195 in Thyroid Carcinoma: Possible Therapeutic

Hamidreza Maroof1, Soussan Irani1,2, Armin Arianna1

  • 1Cancer Molecular Pathology, School of Medicine, Griffith University, Gold Coast, Queensland, Australia.

Current Cancer Drug Targets
|June 30, 2018
PubMed
Abstract

Insights

MicroRNA-195 (miR-195) acts as a tumor suppressor in thyroid carcinoma by targeting VEGF-A and p53. Upregulating miR-195 inhibits cancer cell growth and induces apoptosis, suggesting therapeutic potential.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Clinical and cellular mechanisms of miR-195 in thyroid carcinoma remain uninvestigated.
  • Thyroid carcinoma is a significant health concern with diverse clinical behaviors.

Purpose of the Study:

  • To elucidate the interactions between vascular endothelial growth factor (VEGF), p53, and miR-195 in thyroid carcinoma.
  • To investigate the clinical and pathological relevance of miR-195 in thyroid cancer.

Main Methods:

  • Real-time PCR to quantify miR-195 expression in 123 thyroid carcinomas, metastatic lymph nodes, and control tissues.
  • Western blot and immunofluorescence to assess the impact of exogenous miR-195 on VEGF-A and p53 protein levels.
  • Cell cycle and apoptosis assays to evaluate miR-195's role in cancer cell progression.

Main Results:

  • miR-195 expression was significantly downregulated in most papillary thyroid carcinoma tissues and cell lines.
  • Exogenous miR-195 introduction led to decreased VEGF-A and increased p53 protein expression.
  • Upregulation of miR-195 induced cell cycle arrest and apoptosis in thyroid carcinoma cells.

Conclusions:

  • miR-195 functions as a tumor suppressor in thyroid carcinoma, regulating cell cycle and apoptosis via VEGF-A and p53 targeting.
  • miR-195 represents a promising therapeutic target for aggressive thyroid carcinomas.
Keywords:
VEGF-AangiogenesismiR-195microRNAp53thyroid carcinoma.

More Related Videos

Spontaneous Murine Model of Anaplastic Thyroid Cancer05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

2.3K
Transoral Robotic Total Thyroidectomy and Bilateral Central Regional Lymph Node Dissection for Papillary Thyroid Carcinoma04:01

Transoral Robotic Total Thyroidectomy and Bilateral Central Regional Lymph Node Dissection for Papillary Thyroid Carcinoma

Published on: September 15, 2023

1.5K

Related Concept Videos

The Thyroid Gland01:23

The Thyroid Gland

The thyroid gland is a small, butterfly-shaped gland located in the neck and covers the anterior surface of the trachea. The gland has two lateral lobes connected by a thin tissue mass called the isthmus. Internally, each lobe comprises many small spherical structures known as thyroid follicles, surrounded by a network of blood vessels.
The follicles have a central cavity lined by simple cuboidal to squamous epithelial cells called follicular cells. These cells produce the glycoprotein...
7.7K
Functions of Thyroid Hormones01:18

Functions of Thyroid Hormones

The thyroid hormone (TH) plays a pivotal role in the intricate orchestration of physiological processes, exerting profound effects on development, metabolism, and homeostasis throughout different life stages.
TH is indispensable for the normal development and maturation of the skeletal, muscular, and nervous systems during fetal and childhood growth. It facilitates bone mineral turnover and regulates protein synthesis in developing tissues, contributing significantly to overall growth and...
5.7K
Aggression01:47

Aggression

Humans engage in aggression when they seek to cause harm or pain to another person. Aggression takes two forms depending on one’s motives: hostile or instrumental. Hostile aggression is motivated by feelings of anger with intent to cause pain; a fight in a bar with a stranger is an example of hostile aggression. In contrast, instrumental aggression is motivated by achieving a goal and does not necessarily involve intent to cause pain (Berkowitz, 1993); a contract killer who murders for...
30.4K
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
7.9K
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
240
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
3.9K